TargetMol

tafamidis meglumine

Product Code:
 
TAR-T7582
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T7582-5mg5mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7582-1mL1 mL * 10 mM (in DMSO)£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7582-10mg10mg£135.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7582-25mg25mg£195.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7582-50mg50mg£262.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7582-100mg100mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T7582-500mg500mg£768.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Tafamidis meglumine is a Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid Cascade
CAS:
951395-08-7
Formula:
C21H24Cl2N2O8
Molecular Weight:
503.33
Purity:
0.9998
SMILES:
CNCC(O)C(O)C(O)C(O)CO.OC(=O)c1ccc2nc(oc2c1)-c1cc(Cl)cc(Cl)c1

References

Bulawa C E , Connelly S , Devit M , et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade[J]. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(24):p.9629-9634. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.[J]. The New England journal of medicine, 2018.